<DOC>
	<DOCNO>NCT01568411</DOCNO>
	<brief_summary>This study examine effect inhibitor cytochrome P450 isoenzyme 3A4 ( CYP3A4 ) permeability glycoprotein 1 ( P gp ) ( 200 mg itraconazole ) PK disposition 10 mg tablet TD- 1211 administer orally fast subject .</brief_summary>
	<brief_title>A Fixed−Sequence , Two−Period , Open−Label Drug−Drug Interaction Study Assess Effect Inhibitor Cytochrome P450 Isoenzyme 3A4 Permeability Glycoprotein 1 Pharmacokinetics TD−1211</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>1 . Willing able give write , sign inform consent 2 . Male female subject 18 50 year age ( inclusive ) 3 . Body mass index 19 30 kg/m2 ( inclusive ) , weigh least 55 kg 4 . No clinically important abnormal physical finding screen Period 1 , Day 1 examination 5 . Normal blood pressure ( BP ) heart rate ( HR ) . These measure resting seat supine approximately 5 minute . Normal BP define 90 140 mm Hg systolic 50 85 mm Hg diastolic . Normal HR define 45 90 beat per minute 6 . Negative hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) antibody within last 3 month ( documentation must provide confirmation ) 7 . No clinically relevant abnormality result Screening Period 1 , Day 1 laboratory evaluation 8 . Ability communicate effectively Investigator comply study requirement , restriction , direction clinic staff 9 . For woman childbearing potential , documentation negative serum pregnancy test Screening negative urine pregnancy test Period 1 , Day 1 . Female subject breast feeding . All female subject childbearing potential must use highly effective method birth control study least 1 month completion study drug dosing . A highly effective method birth control define one result low failure rate ( i.e. , &lt; 1 % per year ) use consistently correctly , condom + diaphragm , condom + spermicide , diaphragm + spermicide , IUD document failure rate &lt; 1 % per year , oral/injectable/implanted hormonal contraceptive use combination additional double barrier method , sexual abstinence . Women consider childbearing potential total hysterectomy bilateral tubal ligation least 2 year postmenopausal 10 . All male subject must agree use highly effective method birth control partner childbearing potential study 1 month study dose 1 . Have evidence history clinically significant allergic ( except untreated , asymptomatic , seasonal allergy time dose ) , hematological , endocrine , pulmonary , GI , cardiovascular , hepatic , psychiatric , neurological disease 2 . Any condition possibly affect drug absorption ( e.g. , previous surgery GI tract [ include removal part stomach , bowel , liver , gall bladder , pancreas ] ) 3 . Any condition , opinion Investigator , would confound interfere study participation ; evaluation safety , tolerability , PK investigational drug ; prevent compliance study protocol 4 . Have participate another clinical trial investigational drug ( medical device ) within 30 day ( 5 half life investigational drug longer 30 day ) prior Screening , currently participate another trial investigational drug ( medical device ) , intend participate another trial investigational drug ( medical device ) completion schedule safety evaluation trial 5 . Unwilling abstain ingestion caffeine xanthine contain product ( e.g. , tea , coffee , chocolate , cola , etc . ) begin 48 hour dose study medication ( Day 1 ) final PK sample period 6 . History hypersensitivity drug clinically significant reaction 7 . Any history alcoholism drug abuse ( past year ) positive screen drug abuse alcohol Screening Day 1 period . 8 . Unwilling abstain alcohol begin 48 hour prior study dose administration ( Day 1 ) collection final PK sample period . 9 . Use used tobacco contain product ( e.g. , cigarette , cigar , chew tobacco , snuff , etc . ) within 6 month prior Screening 10 . Consumed grapefruit and/or grapefruit contain juice within 14 day , apple orange juice within 7 day prior admission unit Period 1 , Day 1 11 . Unwilling abstain ingestion grapefruit , orange apple juice throughout duration study include washout period . 12 . Unwilling abstain strenuous physical exercise ( weight training , aerobics ) 48 hour screen examination 72 hour prior study drug administration ( Day 1 ) collection final PK sample period 13 . Acute illness ( GI illness , infection [ e.g. , influenza ] known inflammatory process ) screen and/or admission clinical research unit Period 1 14 . Use prescription drug chronic counter medication include herbal within 7 day ( 14 day drug potential inducer inhibitor CYP3A4 P gp [ e.g. , St John 's Wort , rifampin , cyclosporine , ritonavir ] ) five half life ( whichever longer ) prior Period 1 , Day −1 require continue use study participation , follow exception : Routine vitamin mineral Contraceptives hormone replacement therapy ( HRT ) A daily dose acetaminophen ( 1000 mg ) ibuprofen ( 400 mg ) require study 15 . Have donate blood blood component within 8 week prior Screening . The investigator instruct subject participate study donate blood blood component 8 week completion study 16 . Have abnormal screening ECG indicate second third degree AV block , one following : QRS &gt; 110 msec , QTc F &gt; 450 msec , PR interval &gt; 240 msec . Any rhythm sinus rhythm , interpret investigator clinically significant 17 . Personal family history congenital long QT syndrome family history sudden death 18 . Known hypersensitivity towards intolerance TD 1211 , itraconazole , formulation excipients contain TD 1211 itraconazole 19 . Previous participation another trial TD 1211 20 . Subjects , reason , deem investigator inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>None - normal volunteer</keyword>
</DOC>